NCT03611751 | Study Connect

Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others.

* Required field

Your Email Address *

Please enter valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required field.

Please Log In/Join Now first, and then use this function!

Recruiting

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis - IM011-047

Updated: 14 August, 2018 | ClinicalTrials.gov

About This Trial
Key Eligibility Criteria
Trial Site Locations

Contact us for help
855-907-3286

CONSIDERING THIS TRIAL?

Print this page and the trial guide to help you talk with your doctor.

Use the trial guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Print this page IM011-047

Download Guide

SELECT LANGUAGE

Trial Details

Phase 3

Phase
Gender(s)
18+

Age Range
148

Location(s)
Recruiting

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Active Comparator: Active comparator

Drug: Apremilast

Experimental: BMS-986165

Drug: BMS-986165

Placebo Comparator: Placebo

Other: Placebo

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Plaque psoriasis for at least 6 months - Moderate to severe disease - Candidate for phototherapy or systemic therapy Exclusion Criteria: - Other forms of psoriasis - History of recent infection - Prior exposure to BMS-986165 or active comparator Other protocol defined inclusion/exclusion criteria could apply

Have questions? Call 855-907-3286 or Email Us

Have questions?

Call 855-907-3286 or Email Us